Related references
Note: Only part of the references are listed.Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin
Juliann Chmielecki et al.
ONCOLOGIST (2015)
HER2/neu testing in primary colorectal carcinoma
B. Ingold Heppner et al.
BRITISH JOURNAL OF CANCER (2014)
HER2 testing: Current status and future directions
Edith A. Perez et al.
CANCER TREATMENT REVIEWS (2014)
Human epidermal receptor 2-amplified salivary duct carcinoma: Regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment
Gerald S. Falchook et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2014)
Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status
Tao Wang et al.
HUMAN PATHOLOGY (2014)
HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression
An Na Seo et al.
PLOS ONE (2014)
Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
Filip Janku et al.
CELL REPORTS (2014)
A ssessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
David D. Stenehjem et al.
BREAST CANCER-TARGETS AND THERAPY (2014)
Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study
Zsuzsanna Varga et al.
BMC CANCER (2013)
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)
Edith A. Perez et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment
Valentina Nardi et al.
CLINICAL CANCER RESEARCH (2013)
HER2 testing in esophageal adenocarcinoma (EAC) using parallel tissue-based methods.
Harry H. Yoon et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Non-Small-Cell Lung Cancer with HER2 Exon 20 Mutation Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment
Gerald S. Falchook et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors
Matthew D. Galsky et al.
INVESTIGATIONAL NEW DRUGS (2012)
HER2 Mutations in Non-Small-Cell Lung Cancer Can Be Continually Targeted
Ronan J. Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
HER2 testing in gastric cancer: a practical approach
Josef Rueschoff et al.
MODERN PATHOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Her2 Amplification is Significantly More Frequent in Lymph Node Metastases From Urothelial Bladder Cancer Than in the Primary Tumours
Achim Fleischmann et al.
EUROPEAN UROLOGY (2011)
Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients
M. Lae et al.
ANNALS OF ONCOLOGY (2010)
Genetic and Expression Analysis of HER-2 and EGFR Genes in Salivary Duct Carcinoma: Empirical and Therapeutic Significance
Michelle D. Williams et al.
CLINICAL CANCER RESEARCH (2010)
HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing
Josef Rueschoff et al.
VIRCHOWS ARCHIV (2010)
Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
Guido Sauter et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases
Michael C. Heinrich et al.
CLINICAL CANCER RESEARCH (2008)
Assessment of a HER2 scoring system for gastric cancer:: results from a validation study
M. Hofmann et al.
HISTOPATHOLOGY (2008)
High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system
Allen M. Gown et al.
MODERN PATHOLOGY (2008)
No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas
Vildan Caner et al.
PATHOLOGY & ONCOLOGY RESEARCH (2008)
Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
D. Yoshikawa et al.
BRITISH JOURNAL OF CANCER (2008)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer
F Cappuzzo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
HER 2/neu protein expression in colorectal cancer
B. Schuell et al.
BMC CANCER (2006)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
HER2 expression in cervical cancer as a potential therapeutic target -: art. no. 59
A Chavez-Blanco et al.
BMC CANCER (2004)
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
T Holbro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors
TPJ Garrett et al.
MOLECULAR CELL (2003)
Share Paper
